Skip to content

Sleep Disorders After TIPS

The Incidence of Sleep Disorders After Transjugular Intrahepatic Portosystemic Shunt

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03685994
Enrollment
100
Registered
2018-09-26
Start date
2018-08-31
Completion date
2020-08-31
Last updated
2019-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Disorder

Brief summary

The Purpose of a study to investigate the incidence of postoperative sleep disorders in patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the relationship between risk factors and prognosis of sleep disorders.

Interventions

None listed

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. History of cirrhosis (clinical or by liver biopsy) 2. Portal hypertension patients with defined indications for TIPS treatment 3. Aged 18-75 years old 4. Signed written informed consent

Exclusion criteria

1. mental or nervous system diseases 2. Patients with alcoholic cirrhosis who are still drinking 3. Accompanied by serious heart, lung, brain and kidney diseases 4. Preoperative diagnosis of sleep disorder 5. Patients who are illiteracy 6. The total score of the preoperative Hamilton anxiety scale was greater than or equal to 14 points, and the total score of 17 points of the Hamilton depression scale was greater than or equal to 18 points

Design outcomes

Primary

MeasureTime frameDescription
The incidence of sleep disorders after TIPS1 yearThe number of patients who suffer from sleep disorders after TIPS

Secondary

MeasureTime frameDescription
Incidence of hepatic encephalopathy1 yearThe number of patients who suffer from hepatic encephalopathy
mortality1 yearThe number of patients who died

Countries

China

Contacts

Primary ContactXufeng Luo, MD
luo_xuefeng@yeah.net+86 13880098212

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026